Angiodynamic Inc ANGO Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$11.73 down $0.08, 0.68% at close Nov 6
Last close · Previous close $11.81
- Market cap
- $484.83MAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.78Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$11.73down $0.08, 0.68%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$11.81Nov 5
- Volume363.72KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume877.41KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $9.39 to $16.29; now $11.73
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ANGO trailed the S&P 500 in all 7 periods.
| Period | ANGO and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ANGO: down 18.7% S&P 500: down 5.6% | ANGO trailed the S&P 500 by 13.1 percentage points Trailed |
| 3M | ANGO: down 22.4% S&P 500: down 4.1% | ANGO trailed the S&P 500 by 18.3 percentage points Trailed |
| YTD | ANGO: down 8.6% S&P 500: up 8.7% | ANGO trailed the S&P 500 by 17.3 percentage points Trailed |
| 1Y | ANGO: unchanged S&P 500: up 10.9% | ANGO trailed the S&P 500 by 10.9 percentage points Trailed |
| Long term | ||
| 3Y | ANGO: up 74.6% S&P 500: up 75.0% +20.4% vs +20.5% a year | ANGO trailed the S&P 500 by 0.4 percentage points Trailed |
| 5Y | ANGO: down 62.1% S&P 500: up 67.8% −17.6% vs +10.9% a year | ANGO trailed the S&P 500 by 129.9 percentage points Trailed |
| 10Y | ANGO: down 26.0% S&P 500: up 313.1% −3.0% vs +15.2% a year | ANGO trailed the S&P 500 by 339.1 percentage points Trailed |
$10,000 invested in ANGO 10 years ago (Nov 4, 2016) would be worth about $7,401 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
ANGO beat the S&P 500 in 1 of 7 periods.
| Period | ANGO and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ANGO: down 18.7% S&P 500: down 5.6% | ANGO trailed the S&P 500 by 13.1 percentage points Trailed |
| 3M | ANGO: down 22.4% S&P 500: down 4.3% | ANGO trailed the S&P 500 by 18.1 percentage points Trailed |
| YTD | ANGO: down 8.6% S&P 500: up 7.8% | ANGO trailed the S&P 500 by 16.4 percentage points Trailed |
| 1Y | ANGO: unchanged S&P 500: up 9.7% | ANGO trailed the S&P 500 by 9.7 percentage points Trailed |
| Long term | ||
| 3Y | ANGO: up 74.6% S&P 500: up 68.8% +20.4% vs +19.1% a year | ANGO beat the S&P 500 by 5.8 percentage points Beat |
| 5Y | ANGO: down 62.1% S&P 500: up 56.9% −17.6% vs +9.4% a year | ANGO trailed the S&P 500 by 119.0 percentage points Trailed |
| 10Y | ANGO: down 26.0% S&P 500: up 252.6% −3.0% vs +13.4% a year | ANGO trailed the S&P 500 by 278.6 percentage points Trailed |
$10,000 invested in ANGO 10 years ago (Nov 4, 2016) would be worth about $7,401 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$31.07
Closing high on . Now 62.2% below that record.
Split-adjusted daily closes since Jun 1, 2004.
Stock splits
ANGO hasn’t split since its price history begins in 2004.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Aug 31, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$0.78 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 1.5×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 3.0×Book value as of Aug 31, 2026
Price relative to accounting equity (book value) per share on the Aug 31, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −0.80%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $450.86MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Aug 31, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own ANGO DCF in Excel. Value Angiodynamic with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY27, the quarter ended Aug 31, 2026. “Last 12 months” means the four quarters from Sep 1, 2025 to Aug 31, 2026, and balance-sheet figures are as of Aug 31, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $325.38Mup 8.2%
- Net income
- −$32.94M
- Diluted EPS
- −$0.78
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY25 (Nov 30, 2024) | $72.85M | −$10.74M | −$0.26 |
| Q3 FY25 (Feb 28, 2025) | $72.00M | −$4.41M | −$0.11 |
| Q4 FY25 (May 31, 2025) | $80.16M | −$6.05M | −$0.15 |
| Q1 FY26 (Aug 31, 2025) | $75.71M | −$10.90M | −$0.26 |
| Q2 FY26 (Nov 30, 2025) | $79.43M | −$6.35M | −$0.15 |
| Q3 FY26 (Feb 28, 2026) | $78.42M | −$8.08M | −$0.19 |
| Q4 FY26 (May 31, 2026) | $86.61M | −$11.41M | −$0.27 |
| Q1 FY27 (Aug 31, 2026) | $80.92M | −$7.10M | −$0.17 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY22 (May 31, 2022) | $316.22M | −$26.55M | −$0.68 |
| FY23 (May 31, 2023) | $338.75M | −$52.44M | −$1.33 |
| FY24 (May 31, 2024) | $303.91M | −$184.35M | −$4.59 |
| FY25 (May 31, 2025) | $292.50M | −$33.99M | −$0.83 |
| FY26 (May 31, 2026) | $320.17M | −$36.74M | −$0.88 |
Margins
- Gross 55.7%
- Operating −10.0%
- Net −10.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$3.87MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$3.67MLast 12 months
- Capital spending$7.55MLast 12 months
- −1.2%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $705.00KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $33.97MAs of Aug 31, 2026
Cash plus short- and long-term marketable securities on the Aug 31, 2026 balance sheet.
- Total debt$0.00As of Aug 31, 2026
- Net cash$33.97MAs of Aug 31, 2026
- 2.40As of Aug 31, 2026
Current assets divided by current liabilities on the Aug 31, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Aug 31, 2026
Total debt divided by shareholders’ equity on the Aug 31, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 6 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −19.2%Last 12 months
Over the last 12 months, Angiodynamic lost money: its net loss was 19.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −12.7%Last 12 months
Over the last 12 months, Angiodynamic’s net loss was 12.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Angiodynamic Inc
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients. The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Headquarters
- New York, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ANGO news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ANGO stock FAQ
What is ANGO stock’s price today?
Angiodynamic (ANGO) traded at $11.73 at the close on , down $0.08 (0.68%) from the previous close of $11.81. Over the past 52 weeks it has traded between $9.39 and $16.29.
If you invested $1,000 in ANGO 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ANGO on would be worth about $740 at the close on , a total return of −26.0%. The same $1,000 would be worth $379 if invested five years ago, $1,000 if invested one year ago, and $544 if invested 20 years ago. Past performance doesn’t predict future returns.
What is Angiodynamic’s market cap?
Angiodynamic’s market capitalization is about $484.8 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $11.73 (how market cap works). Angiodynamic reported 41.33M shares outstanding at the end of its latest quarter ().
What is ANGO’s P/E ratio?
ANGO’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.78).
How much revenue does Angiodynamic make?
Angiodynamic reported $325.4 million of revenue over the four quarters to , up 8.2% from the twelve months before. In its latest quarter (Q1 FY27, ended ) revenue was $80.9 million, up 6.9% from a year earlier.
Is Angiodynamic profitable?
Not over the four quarters to . Angiodynamic reported a net loss of $32.9 million across those four quarters on $325.4 million of revenue.
What are ANGO’s earnings per share?
ANGO’s diluted earnings per share were −$0.78 over the four quarters to , compared with −$0.78 in the twelve months before. The latest quarter (Q1 FY27) brought −$0.17 per share, against −$0.26 a year earlier (how EPS works).
Does ANGO pay a dividend?
Angiodynamic hasn’t paid a dividend in the last twelve months.
What is ANGO’s 52-week high and low?
Over the past 52 weeks ANGO has traded as low as $9.39 and as high as $16.29. At $11.73 at the close on , it is 28.0% below that high and 24.9% above the low.
What is ANGO’s all-time high?
ANGO’s highest closing price was $31.07 on , adjusted for stock splits. At $11.73 at the close on , it is 62.2% below that record.
Has ANGO stock ever split?
No. ANGO hasn’t split since its price history begins in 2004.
How has ANGO stock performed?
Including dividends and measured to the close on , ANGO has returned −8.6% so far this year and 0.0% over the past year, and −62.1% over five years (−17.6% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Angiodynamic in?
Angiodynamic is in the Healthcare sector and the Medical Instruments & Supplies industry, and is headquartered in New York, USA.
What exchange does ANGO trade on?
Angiodynamic trades on the Nasdaq under the ticker symbol ANGO. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.